Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
166
self-reported band not used
Founded
2020
6 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
2
Grant · May 2023 · US$ 3.3M
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
BIOCINA PTY LTD
ABN71640133348
Legal entities
Show as table · BioCina: 1 registry entity
| BIOCINA PTY LTD | ABN 71640133348 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
BioCina is a global end-to-end CDMO delivering exceptional quality, regulatory excellence, and industry-leading on-time, in-full delivery. With deep expertise in small molecules, microbial, pDNA, and mRNA, we offer cell line, process, analytical, and formulation development, plus cGMP clinical and commercial manufacturing.
We operate two state-of-the-art facilities in Adelaide and Perth, led by highly experienced SMEs with an average tenure of 10+ years. Our sites are licensed by the Australian TGA and have passed inspections by the US FDA, EMA, and Health Canada.
With a proven track record of supplying drug substance and sterile drug product to 98 countries, BioCina proudly serves clients across every major global market. Because we are not a drug developer, our sole focus is on advancing our clients’ products.
Australia also offers one of the world’s most generous R&D tax incentives, up to 48.5% cash back, making BioCina an ideal partner for scaling and manufacturing.
Specialties
All 20 specialties
- Microbial Fermentation
- Plasmid DNA
- mRNA Manufacturing
- Minicircle DNA
- LNP Formulation
- Process Development
- Analytical Development
- GMP Manufacturing
- Tech Transfer
- Quality Assurance
- Cell Banking
- MCB/WCB Production
- Scale Up
- Regulatory Support
- Purification
- Formulation
- Fill-Finish
- CDMO Services
- Biologics
- Sterile Manufacturing
Related specialties
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU8 Dalgleish St; Thebarton, South Australia 5031Primary
Grid intelligence Members
Funding
Rounds2
Round typeGrant · non-equity funding
Amount (USD)3,300,000
Stage rank1
Investors named1
Since last round2 yr 7 mo
Funding
Show as table · 2 funding rounds
| Rounds | 2 |
|---|---|
| Axis | 2020 to 2026 |
| Grant · 26 May 2023 | US$ 3.3M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
Which legal entity operates under BioCina?
One New South Wales entity on the ABR: BIOCINA PTY LTD (ABN 71 640 133 348), high confidence.
How many people work at BioCina?
166 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does BioCina have offices?
One address on record, Australia only. Primary: 8 Dalgleish St, Thebarton, South Australia 5031.
Has BioCina raised funding?
Two rounds. Latest 26 May 2023: grant, US$3,300,000, investor National Health and Medical Research Council.
What does BioCina list as its specialties?
20 tags on the brand's own list, among them process development and quality assurance.
Which companies are listed alongside BioCina?
36 profiles list BioCina as a peer — 97th percentile in Pharmaceutical Manufacturing. It lists ten peers of its own. Mayne Pharma Australia and CMAX Clinical Research list it back.